 |
| |
| May-07-20 | Reiterated |
H.C. Wainwright |
Buy |
$37 → $31 |
|
| Jan-10-20 | Initiated |
BofA/Merrill |
Neutral |
$27 |
|
| Jan-09-20 | Initiated |
SunTrust |
Buy |
$32 |
|
| Dec-19-19 | Initiated |
Citigroup |
Buy |
$36 |
|
| Nov-07-19 | Reiterated |
H.C. Wainwright |
Buy |
$55 → $41 |
|
| Oct-30-19 | Reiterated |
Needham |
Buy |
$54 → $48 |
|
| Aug-08-19 | Reiterated |
Needham |
Buy |
$74 → $54 |
|
| Aug-08-19 | Reiterated |
Cantor Fitzgerald |
Overweight |
$85 → $62 |
|
| Mar-21-19 | Initiated |
Piper Jaffray |
Overweight |
$80 |
|
| Jul-13-18 | Reiterated |
Needham |
Buy |
$76 → $86 |
|
| Feb-16-18 | Resumed |
H.C. Wainwright |
Buy |
$78 |
|
| Jan-26-18 | Initiated |
Seaport Global Securities |
Buy |
$78 |
|
| Oct-24-17 | Initiated |
Guggenheim |
Buy |
$80 |
|
| Oct-16-17 | Reiterated |
Needham |
Buy |
$65 → $76 |
|
| Jul-20-17 | Reiterated |
Cantor Fitzgerald |
Overweight |
$56 → $62 |
|
| May-25-17 | Reiterated |
Needham |
Buy |
$58 → $65 |
|
| Mar-09-17 | Downgrade |
Raymond James |
Strong Buy → Mkt Perform |
|
|
| Mar-08-17 | Reiterated |
RBC Capital Mkts |
Outperform |
$54 → $55 |
|
| Mar-08-17 | Reiterated |
Needham |
Buy |
$52 → $58 |
|
| Feb-17-17 | Initiated |
ROTH Capital |
Buy |
$69 |
|
|
|
| May-26-20 12:36AM | Edited Transcript of AERI earnings conference call or presentation 6-May-20 9:00pm GMT Thomson Reuters StreetEvents |
| May-11-20 07:15PM | Was The Smart Money Right About Aerie Pharmaceuticals Inc (AERI)? Insider Monkey +5.04% |
| May-07-20 06:30PM | Aerie Pharmaceuticals Inc (AERI) Q1 2020 Earnings Call Transcript Motley Fool -7.79% |
| May-06-20 05:15PM | Aerie Pharmaceuticals (AERI) Reports Q1 Loss, Lags Revenue Estimates Zacks |
| 04:01PM | Aerie Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update Business Wire |
| 03:00PM | Aerie Pharmaceuticals, Inc. to Host Earnings Call ACCESSWIRE |
| May-05-20 07:30AM | Aerie Pharmaceuticals to Present at the Bank of America Securities 2020 Healthcare Conference Business Wire |
| Apr-29-20 07:30AM | Aerie Pharmaceuticals to Announce First Quarter 2020 Financial Results and Host Conference Call on Wednesday, May 6, 2020 Business Wire +9.81% |
| Apr-28-20 12:34PM | Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: Should You Buy? Zacks -5.22% |
| Apr-13-20 10:01AM | Aerie (AERI) Suspends Guidance Due to Coronavirus Outbreak Zacks |
| Apr-09-20 04:01PM | Aerie Pharmaceuticals Provides 2020 Company and Guidance Update Associated with COVID-19 Business Wire +13.81% |
| Apr-07-20 07:30AM | Aerie Pharmaceuticals to Present at the Needham Virtual Healthcare Conference Business Wire +5.92% |
| Apr-02-20 02:54PM | Gone: Triangle public companies lose $30 billion in value during 1Q 2020 American City Business Journals |
| Mar-25-20 10:18AM | Healthcare Pro James Flynn Picks up These 3 Stocks on the Cheap TipRanks |
| Mar-21-20 11:30AM | Why Is Aerie (AERI) Down 40.5% Since Last Earnings Report? Zacks |
| Feb-27-20 07:23AM | Edited Transcript of AERI earnings conference call or presentation 20-Feb-20 10:00pm GMT Thomson Reuters StreetEvents -9.18% |
| 05:19AM | Aerie Pharmaceuticals, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates Simply Wall St. |
| Feb-24-20 02:59PM | Advance Auto Parts, Cree among Triangle companies hit as stocks tumble with rising concern over coronavirus American City Business Journals -5.97% |
| 07:30AM | Aerie Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference Business Wire |
| Feb-21-20 11:30AM | Aerie's (AERI) Q4 Loss Wider Than Expected, Revenues Beat Zacks +8.55% |
| 07:46AM | The Daily Biotech Pulse: FDA Approves Baudax Bio's Non-Opioid Pain Drug, Aerie Rallies On Q4 Results, D-Day For Esperion Benzinga |
| Feb-20-20 05:35PM | Aerie Pharmaceuticals (AERI) Reports Q4 Loss, Tops Revenue Estimates Zacks |
| 04:01PM | Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results, Provides 2020 Guidance and Business Update Business Wire |
| 10:50AM | Some Market Stats In 5 Minutes Benzinga |
| Feb-18-20 06:30AM | Aerie Pharmaceuticals Announces Appointment of Nina Ohara, PharmD, M.B.A, as Director, Marketing and Gregory Jones, CPA, as Director, Tax Business Wire |
| Feb-13-20 07:30AM | Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call on Thursday, February 20, 2020 Business Wire |
| Feb-12-20 05:13AM | Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St. |
| Feb-03-20 06:30AM | Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, Ph.D., as Vice President, Clinical Development and Medical Affairs Business Wire |
| Jan-21-20 06:30AM | Aerie Pharmaceuticals Announces U.S. Food and Drug Administration Approval of its Athlone, Ireland Facility for Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Business Wire |
| Jan-08-20 05:18PM | How Did Aerie Pharmaceuticals Inc (AERI) Perform In Comparison to Hedge Fund Favorites in 2019? Insider Monkey |
| Jan-07-20 05:26AM | Does Aerie Pharmaceuticals (NASDAQ:AERI) Have A Healthy Balance Sheet? Simply Wall St. |
| Jan-03-20 10:04AM | Aerie's (AERI) Application for Roclanda Accepted in Europe Zacks |
| Jan-02-20 08:46AM | The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe Benzinga |
| 06:30AM | Aerie Pharmaceuticals Announces Acceptance for Review of the Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% Marketing Authorisation Application in Europe Business Wire |
| Dec-09-19 06:30AM | Aerie Pharmaceuticals Announces Appointment of Amine Sinmazisik as Director, Finance Business Wire +5.91% |
| Dec-06-19 11:31AM | Aerie (AERI) Up 4.7% Since Last Earnings Report: Can It Continue? Zacks |
| Dec-04-19 09:19AM | Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy ? Insider Monkey +6.32% |
| Dec-03-19 06:15AM | Aerie Pharmaceuticals Submits Marketing Authorisation Application for Roclanda® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in Europe Business Wire |
| Dec-02-19 04:56AM | Did Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Insiders Buy Up More Shares? Simply Wall St. |
| Nov-27-19 09:45AM | 5 Strong Buy Biotech Stocks With More Than 80% Upside InvestorPlace |
| Nov-26-19 06:30AM | Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference TEST Business Wire Releases |
| 06:30AM | Aerie Pharmaceuticals to Present at the Piper Jaffray 31st Annual Healthcare Conference Business Wire |
| Nov-22-19 08:18AM | The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate Benzinga |
| Nov-21-19 06:30AM | Aerie Pharmaceuticals Receives European Commission Approval for Rhokiinsa® (netarsudil ophthalmic solution) 0.02% Business Wire |
| Nov-19-19 10:58AM | Aerie buys Spanish outfit as it moves toward profitability American City Business Journals |
| 09:31AM | Aerie to Acquire Dry Eye Disease-Focused Pharma Avizorex Zacks |
| Nov-18-19 06:30AM | Aerie Pharmaceuticals Announces Agreement to Acquire Avizorex Pharma, S.L. to Advance Its Dry Eye Program Business Wire |
| Nov-12-19 07:30AM | Aerie Pharmaceuticals to Present at the Stifel 2019 Healthcare Conference Business Wire |
| 05:41AM | Edited Transcript of AERI earnings conference call or presentation 6-Nov-19 10:00pm GMT Thomson Reuters StreetEvents |
| Nov-07-19 10:51AM | Aerie (AERI) Q3 Loss Wider, Sales Beat, Guidance Slashed Zacks -22.42% |
| 07:18AM | The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs Benzinga |
| Nov-06-19 06:05PM | Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates Zacks |
| 04:01PM | Aerie Pharmaceuticals Reports Third Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire |
| Nov-05-19 06:30AM | Aerie Pharmaceuticals Announces Positive Topline Results for Netarsudil Ophthalmic Solution in Phase 2 Study Conducted in Japan Business Wire |
| Oct-30-19 07:30AM | Aerie Pharmaceuticals to Announce Third Quarter 2019 Financial Results and Host Conference Call on Wednesday, November 6, 2019 Business Wire |
| 06:30AM | Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, M.D., M.B.A., as Chief Research & Development Officer Business Wire |
| Oct-29-19 10:33AM | Aerie Pharmaceuticals (AERI) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks |
| Oct-28-19 06:13PM | Is Aerie Pharmaceuticals Inc (AERI) Going To Burn These Hedge Funds ? Insider Monkey +5.44% |
| Oct-25-19 06:40AM | Imagine Owning Aerie Pharmaceuticals (NASDAQ:AERI) While The Price Tanked 62% Simply Wall St. |
| Oct-24-19 06:30AM | Aerie Pharmaceuticals Completes Enrollment in the Phase 2 Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion Ahead of Schedule Business Wire |
| Oct-16-19 07:15PM | Edited Transcript of AERI earnings conference call or presentation 7-Aug-19 9:00pm GMT Thomson Reuters StreetEvents |
| Oct-07-19 06:30AM | Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer Business Wire |
| Sep-25-19 07:30AM | Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire |
| Sep-23-19 01:20PM | Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks |
| Sep-20-19 06:30AM | Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union Business Wire |
| Sep-19-19 07:39AM | The Daily Biotech Pulse: China Biologics Receives Buyout Offer, Provention Bio Offering, Exagen IPO Benzinga +5.87% |
| 06:37AM | Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money? Simply Wall St. |
| 06:30AM | Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility Business Wire |
| Sep-16-19 11:46AM | Weekly CEO Buys Highlight GuruFocus.com +7.92% |
| Sep-10-19 09:36PM | Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aeries 1.50% Convertible Senior Notes Due 2024 Business Wire +8.26% |
| Sep-09-19 07:15PM | Aerie Pharmaceuticals Inc (AERI) CEO Vicente Jr Anido Bought $499,012 of Shares GuruFocus.com +8.77% |
| 06:00AM | These 2 Biotech Stocks Are Seeing Insider Buying Activity TheStreet.com |
| Sep-06-19 02:42PM | Durham pharma embarks on $275M financial trade American City Business Journals |
| 09:31AM | Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound? Zacks |
| Sep-05-19 08:12AM | The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug Benzinga |
| Sep-04-19 08:20PM | Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024 Business Wire -9.31% |
| Sep-03-19 04:01PM | Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024 Business Wire -5.82% |
| Aug-26-19 06:30AM | Aerie Pharmaceuticals Announces Appointment of Luis Vargas, M.D., as Medical Director, Medical Affairs Business Wire |
| Aug-20-19 06:30AM | Aerie Pharmaceuticals Initiates First-in-Human Clinical Trial of AR-13503 Sustained Release Intravitreal Implant in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema Business Wire -5.78% |
| Aug-19-19 01:56PM | Zuckerberg Sells Shares of Facebook GuruFocus.com |
| Aug-08-19 04:08PM | This Biotech Crashed On 'Erroneous' Report Plus 2 Stocks That Diverged Investor's Business Daily +6.65% |
| 09:25AM | Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance Zacks |
| 09:02AM | Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability Simply Wall St. |
| 01:50AM | Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript Motley Fool |
| Aug-07-19 06:05PM | Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates Zacks |
| 04:01PM | Aerie Pharmaceuticals Reports Second Quarter 2019 Financial Results, Updates Full-Year 2019 Guidance and Provides Business Update Business Wire |
| Jul-31-19 10:36AM | Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know Zacks |
| Jul-28-19 09:23PM | Analysts Recommend Buying These 2 Falling Knives GuruFocus.com |
| Jul-25-19 07:30AM | Aerie Pharmaceuticals to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019 Business Wire |
| Jul-18-19 06:26PM | Allergan Announces FDA Acceptance of Glaucoma Candidate NDA Zacks |
| 08:22AM | Hatteras Ventures-backed firm adds fresh round of capital American City Business Journals |
| Jul-11-19 06:46AM | How a Durham firm stands to benefit from an unexpected break in a Japanese trial American City Business Journals |
| Jul-09-19 05:48PM | Aerie Completes Enrollment Under Rhopressa Study in Japan Zacks |
| 06:30AM | Aerie Pharmaceuticals Completes Enrollment of the Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Months Ahead of Schedule Business Wire |
| Jun-24-19 08:50AM | Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza Zacks |
| Jun-20-19 07:09PM | Is Aerie Pharmaceuticals Inc (AERI) A Good Stock To Buy? Insider Monkey |
| Jun-17-19 09:47PM | Edited Transcript of AERI earnings conference call or presentation 7-May-19 9:00pm GMT Thomson Reuters StreetEvents |
| 06:30AM | Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting Business Wire |
| Jun-11-19 07:30AM | Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences Business Wire |
| Jun-06-19 01:58PM | Does Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Have A Particularly Volatile Share Price? Simply Wall St. -6.09% |
|
|
|
|
| Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, dry eye, retinal diseases, and other eye diseases. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma and ocular hypertension. The company is also developing AVX-012, a clinical-stage dry eye product candidate; and AR-1105 and AR-13503 sustained-release implants for treating retinal diseases. Aerie Pharmaceuticals, Inc. has a collaborative research, development, and licensing agreement with DSM. Aerie Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Durham, North Carolina. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| GOLDBERG MURRAY A | Director | May 18 | Option Exercise | 3.15 | 28,000 | 88,200 | 36,050 | May 20 06:45 PM | | Cagle Gerald D. | Director | May 08 | Sale | 15.27 | 5,000 | 76,350 | 16,550 | May 12 05:25 PM | | Foresite Capital Management II | 10% Owner | Feb 27 | Sale | 17.07 | 1,000,000 | 17,070,000 | 1,229,633 | Mar 02 05:01 PM | | Kopczynski Casey C. | Chief Scientific Officer | Dec 03 | Option Exercise | 0.41 | 117,000 | 47,385 | 218,511 | Dec 05 04:06 PM | | RUBINO RICHARD J | Chief Financial Officer | Sep 09 | Buy | 19.93 | 5,040 | 100,447 | 339,446 | Sep 09 05:45 PM | | ANIDO VICENTE JR | Chief Executive Officer | Sep 09 | Buy | 19.01 | 26,250 | 498,953 | 197,631 | Sep 09 05:43 PM | | Foresite Capital Management II | 10% Owner | Sep 05 | Buy | 18.42 | 15,700 | 289,194 | 2,350,477 | Sep 06 08:28 PM | | Foresite Capital Management II | 10% Owner | Sep 04 | Buy | 18.48 | 100,200 | 1,851,696 | 2,334,777 | Sep 06 08:28 PM | | Foresite Capital Management II | 10% Owner | Sep 03 | Buy | 20.81 | 50,000 | 1,040,741 | 2,325,477 | Sep 04 08:38 PM | | Foresite Capital Management II | 10% Owner | Aug 30 | Buy | 21.36 | 25,000 | 534,000 | 2,275,477 | Sep 04 08:38 PM | | Foresite Capital Management II | 10% Owner | Aug 23 | Buy | 23.42 | 38,300 | 896,986 | 2,250,477 | Aug 23 08:52 PM | | Foresite Capital Management II | 10% Owner | Aug 22 | Buy | 23.68 | 6,700 | 158,656 | 2,212,177 | Aug 23 08:52 PM | | Foresite Capital Management II | 10% Owner | Aug 21 | Buy | 23.25 | 1,153 | 26,807 | 2,205,477 | Aug 23 08:52 PM | | Foresite Capital Management II | 10% Owner | Aug 20 | Buy | 23.21 | 50,000 | 1,160,500 | 2,204,324 | Aug 20 08:27 PM | | Foresite Capital Management II | 10% Owner | Aug 19 | Buy | 23.34 | 3,847 | 89,789 | 2,154,324 | Aug 20 08:27 PM | | Foresite Capital Management II | 10% Owner | Aug 16 | Buy | 24.23 | 100,000 | 2,423,000 | 2,150,477 | Aug 20 08:27 PM | | Foresite Capital Management II | 10% Owner | Aug 14 | Buy | 23.73 | 100,000 | 2,373,000 | 2,050,477 | Aug 14 08:15 PM | | Foresite Capital Management II | 10% Owner | Aug 13 | Buy | 25.35 | 250,000 | 6,337,342 | 1,310,000 | Aug 14 08:15 PM | | Foresite Capital Management II | 10% Owner | Aug 12 | Buy | 24.43 | 189,555 | 4,630,829 | 1,060,000 | Aug 14 08:15 PM |
|
|
|
|
|
|
